Home » Business » Manufacturing
Novartis swoops on new heart drug
Source: Agencies |
December 24, 2009, Thursday
|
Print Edition
Print Edition
SWISS pharmaceuticals maker Novartis AG said yesterday it would buy United States biopharmaceutical company Corthera Inc for US$120 million, giving it the right to develop a new drug against heart failure.
The acquisition of Corthera is subject to regulatory approval and should be completed by the end of next year, Novartis said.
The privately owned company has been developing relaxin, which is in the third trial phase as a potential treatment for patients with acute heart failure, Novartis said.
Novartis said it would be responsible for completing the development of relaxin and planned to submit requests to put it on the market in the United States and Europe in 2013.
Shares in Novartis were down 0.09 percent at 56.80 Swiss francs (US$54.25) on the Zurich exchange yesterday.
The acquisition of Corthera is subject to regulatory approval and should be completed by the end of next year, Novartis said.
The privately owned company has been developing relaxin, which is in the third trial phase as a potential treatment for patients with acute heart failure, Novartis said.
Novartis said it would be responsible for completing the development of relaxin and planned to submit requests to put it on the market in the United States and Europe in 2013.
Shares in Novartis were down 0.09 percent at 56.80 Swiss francs (US$54.25) on the Zurich exchange yesterday.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
